Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov 30;18(5):2045153.
doi: 10.1080/21645515.2022.2045153. Epub 2022 Mar 3.

Post COVID-19 vaccination Guillain-Barre syndrome: three cases

Seyedehnarges Tabatabaee  1 , Fatemeh Rezania  2 , Sayed Mohammed Jawad Alwedaie  3 , Ensieh Malekdar  4 , Zahra Badi  5 , Seyed Mohammad Tabatabaei  6 , Zahra Mirzaasgari  1   7
Affiliations
Case Reports

Post COVID-19 vaccination Guillain-Barre syndrome: three cases

Seyedehnarges Tabatabaee et al. Hum Vaccin Immunother. .

Abstract

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. Temporally associated cases of GBS following COVID-19 vaccination have been described with different COVID-19 vaccines. In this study, we report three cases of GBS patients following COVID-19 vaccine. Two of the studied patients received the Sinopharm vaccine and one patient received the AstraZeneca vaccine. All patients were diagnosed with acute motor axonal neuropathy (AMAN) type of GBS, on nerve conduction studies. All three patients responded well to treatment with intravenous immunoglobulin (IVIg). The association between COVID-19 vaccination and GBS is not well understood and more studies are needed to establish whether it is merely an association or a causal relationship.

Keywords: AstraZeneca; Coronavirus 2019; Guillain-Barre syndrome; Sinopharm; vaccine.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

References

    1. Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira ML, Cornblath DR, van Doorn PA, Dourado ME, Hughes RA, Islam B, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–5. doi:10.1038/s41582-019-0250-9. - DOI - PMC - PubMed
    1. Govoni V, Granieri E.. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol. 2001;14(5):605–13. doi:10.1097/00019052-200110000-00009. - DOI - PubMed
    1. Abolmaali M, Heidari M, Zeinali M, Moghaddam P, Ghamsari MR, Makiani MJ, Mirzaasgari Z.. Guillain–barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series. J Clin Neurosci. 2021;83:119–22. doi:10.1016/j.jocn.2020.11.013. - DOI - PMC - PubMed
    1. Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13(2). doi:10.7759/cureus.13426. - DOI - PMC - PubMed
    1. Loza AMM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology. 2021;96(22):1052–54. doi:10.1212/WNL.0000000000011881. - DOI - PubMed

Publication types

MeSH terms

Substances